List of Excipients in Branded Drug CETIRIZINE HYDROCHLORIDE TABLETS, 5 MG

Generic Drugs Containing CETIRIZINE HYDROCHLORIDE TABLETS, 5 MG

Company	Ingredient	NDC	Excipient
MARKSANS PHARMA LIMITED	cetirizine hydrochloride	25000-219	HYPROMELLOSE
MARKSANS PHARMA LIMITED	cetirizine hydrochloride	25000-219	LACTOSE MONOHYDRATE
MARKSANS PHARMA LIMITED	cetirizine hydrochloride	25000-219	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in CETIRIZINE HYDROCHLORIDE TABLETS, 5 MG?

# Of NDCs	Excipient
1	HYPROMELLOSE
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE

Cetirizine Hydrochloride 5 mg Tablets: Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Cetirizine hydrochloride 5 mg tablets are a low-complexity, mature generic product with limited active-ingredient patent risk and modest manufacturing barriers. Commercial value depends on cost control, excipient differentiation, pediatric usability, allergen positioning, packaging, and channel strategy rather than proprietary chemistry.

The most attractive opportunities are lactose-free tablets, sugar-free chewables, rapidly disintegrating tablets, small-format pediatric products, and private-label or store-brand distribution. A conventional immediate-release tablet remains the lowest-cost benchmark and is likely to face intense price competition.

What is the regulatory status of cetirizine hydrochloride 5 mg tablets?

Cetirizine hydrochloride is a second-generation antihistamine used for allergic rhinitis and chronic urticaria. It is commonly marketed at 5 mg and 10 mg strengths. The 5 mg strength is particularly relevant for pediatric dosing and for adults who require dose reduction because of renal impairment or sedation concerns.

In the United States, cetirizine has both prescription and OTC regulatory history. The original Zyrtec product was approved under NDA 019835, and cetirizine later moved into the OTC market. FDA’s OTC monograph system and marketed monograph products provide an important commercial route for eligible antihistamine products.[1,2]

Regulatory element	Commercial relevance
Active ingredient	Cetirizine hydrochloride
Common strengths	5 mg and 10 mg
Primary dosage forms	Tablets, chewable tablets, oral solution, orally disintegrating products
Therapeutic class	Second-generation H1 antihistamine
U.S. pathway	OTC monograph pathway or ANDA/NDA-based pathway, depending on product design
Reference brand	Zyrtec
Prescription-to-OTC history	Yes
Biosimilar pathway	Not applicable
Primary approval issue	Conformance with applicable monograph or demonstrated pharmaceutical equivalence and bioequivalence

A manufacturer pursuing a standard 5 mg immediate-release tablet should prioritize dosage-form compliance, assay, dissolution, content uniformity, stability, labeling, and inactive-ingredient suitability. Novel excipients are generally unnecessary.

When does cetirizine lose exclusivity, and what patents protect it?

The original cetirizine compound and core product protections are long expired in the United States. Cetirizine is a mature generic active ingredient, and commercial products do not depend on a meaningful surviving composition-of-matter patent estate.

The original cetirizine patent family was associated with UCB and related entities. The relevant U.S. patent protection expired years before the current generic market developed. The original Zyrtec NDA also no longer provides meaningful market exclusivity for ordinary cetirizine hydrochloride tablets.[3]

IP category	Status for conventional cetirizine 5 mg tablets
Composition-of-matter patent	Expired
Original branded tablet protection	Expired
Regulatory exclusivity	Expired
Formulation patent risk	Generally low for standard immediate-release tablets
Method-of-use patent risk	Low for ordinary allergy and urticaria indications
Manufacturing patent risk	Low for conventional tableting
Biosimilar risk	None
Paragraph IV exposure	Low unless a new listed patent covers a specific product or indication

What is the Orange Book status of cetirizine tablets?

The Orange Book is relevant primarily where a product is approved under an NDA and abbreviated applicants reference that product. Cetirizine products have also been marketed under OTC regulatory frameworks, which changes the practical significance of Orange Book listings.

For a conventional 5 mg generic tablet, the principal commercial question is whether the proposed product can be marketed under an applicable OTC monograph or requires an ANDA or other FDA application. The answer depends on formulation, labeling, dosage form, route, strength, and the regulatory status of the proposed product.

A standard tablet with conventional excipients has little reason to create new Orange Book patent exposure. A manufacturer using an innovative delivery system, novel indication, or proprietary formulation should assess whether the product requires NDA approval and whether resulting patents could be listed.

Are Paragraph IV challenges likely for cetirizine 5 mg tablets?

Paragraph IV litigation is unlikely to be a central issue for ordinary cetirizine 5 mg tablets. Paragraph IV certifications challenge patents listed for a reference drug in the Orange Book. Cetirizine’s original active-ingredient and core product protections are expired, and standard generic products have been marketed for many years.

A Paragraph IV risk could arise if a new branded product obtains approval for a specialized formulation, delivery system, or combination. That risk would attach to the new product’s listed patents, not to cetirizine hydrochloride as a mature active ingredient.

Which excipients are used in cetirizine hydrochloride 5 mg tablets?

Commercial cetirizine tablets use conventional tablet excipients. Public labels show variations by manufacturer and dosage form. A typical film-coated immediate-release formulation may contain:

• Lactose monohydrate
• Microcrystalline cellulose
• Povidone
• Croscarmellose sodium or another superdisintegrant
• Colloidal silicon dioxide
• Magnesium stearate
• Hypromellose
• Polyethylene glycol
• Titanium dioxide
• Colorants, where applicable

Inactive ingredients differ across products. DailyMed labels for cetirizine tablets and chewable tablets show that manufacturers use different excipient combinations, including lactose-based and lactose-free systems.[4]

What is the best excipient base for a conventional tablet?

For a low-dose 5 mg tablet, content uniformity is the primary formulation challenge. The active ingredient represents a small fraction of total tablet weight, so the formulation should provide reliable powder blending and low segregation.

A practical conventional formulation uses:

1. Microcrystalline cellulose as the principal diluent.
2. Lactose monohydrate or an alternative filler to achieve target tablet weight.
3. Croscarmellose sodium for rapid disintegration.
4. Colloidal silicon dioxide to improve flow.
5. Magnesium stearate at controlled concentration for lubrication.
6. A film coat based on hypromellose, polyethylene glycol, and pigment or opacifier.

Direct compression is commercially attractive if the active ingredient and excipient grades provide acceptable flow and blend uniformity. Wet granulation may improve uniformity and compressibility but adds equipment, processing time, residual-moisture controls, and scale-up risk.

Should a manufacturer use lactose-free excipients?

Yes, if the product is intended for broad retail positioning or institutional procurement. Lactose-free tablets can avoid sensitivity concerns, simplify label claims, and support differentiation from low-cost legacy products.

Suitable lactose-free fillers include:

• Microcrystalline cellulose
• Mannitol
• Dibasic calcium phosphate
• Pregelatinized starch
• Compressible sucrose, where appropriate

Mannitol is particularly useful for chewable and orally disintegrating products because it provides a cooling mouthfeel and acceptable taste. It increases formulation cost compared with conventional lactose systems.

What formulations are protected by cetirizine patents?

No major surviving patent barrier is expected for standard cetirizine hydrochloride 5 mg tablets. The commercial opportunity is therefore based on formulation execution rather than freedom from a dominant active-ingredient patent.

Potentially differentiable formulations include:

Conventional film-coated tablets

This is the lowest-risk and lowest-cost option. The product should target:

• High blend uniformity
• Fast dissolution
• Low friability
• Consistent tablet hardness
• Stable appearance
• Low packaging cost

The principal weakness is commoditization. Retail buyers can substitute among many products, and pharmacy substitution limits pricing power.

Chewable tablets

Chewables offer stronger pediatric and family-channel positioning. The formulation must address cetirizine’s bitter taste through sweeteners, flavors, taste-masking agents, and an appropriate compression system.

Common excipient strategies include mannitol, sorbitol, sucralose, aspartame, acesulfame potassium, flavor systems, and lubricants compatible with chewable tablets. Sugar-free positioning is commercially useful, but polyol levels must be controlled because excessive quantities can affect gastrointestinal tolerance.

Orally disintegrating tablets

ODTs can target children, older patients, and consumers who have difficulty swallowing conventional tablets. Key performance attributes include:

• Rapid disintegration
• Low tablet friability
• Pleasant mouthfeel
• Low residual grit
• Moisture protection
• Adequate packaging barrier

Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and selected co-processed excipients can support ODT performance. Blister packaging is usually preferable to high-humidity bottle systems.

Pediatric mini-tablets

Mini-tablets can provide a differentiated pediatric product without relying on liquid formulations. A 5 mg tablet can be designed for age-specific administration, but dosing instructions and swallowability must be supported by product-specific data.

This format may have commercial value in markets where caregivers prefer solid dosage forms because of portability, shelf stability, or reduced measuring errors.

How should excipients address cetirizine taste and sedation concerns?

Cetirizine hydrochloride has a bitter taste that becomes more important in chewable and orally disintegrating products. Film coating is generally sufficient for conventional swallowed tablets but does not solve taste exposure after chewing or rapid oral disintegration.

Taste-masking options include:

• Dense polymer coating of active particles
• Ion-exchange resin complexes
• Lipid or wax barriers
• Flavor and sweetener systems
• Multiparticulate incorporation
• Selective use of pH modifiers

Ion-exchange resin systems may create a differentiated formulation but increase development complexity and can affect release testing. A simple coated tablet is more suitable for a price-sensitive generic. A resin-based or multiparticulate product is more suitable for a premium pediatric or ODT strategy.

Sedation is a pharmacologic property of cetirizine and cannot be removed through excipient selection. Product claims must remain consistent with the approved labeling and applicable OTC requirements.[2]

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are low for conventional tablets and moderate for differentiated dosage forms.

Product concept	Manufacturing complexity	IP opportunity	Commercial assessment
Standard film-coated tablet	Low	Low	High price pressure
Lactose-free tablet	Low to moderate	Low	Useful retail differentiation
Chewable tablet	Moderate	Moderate	Strong pediatric and family positioning
ODT	Moderate to high	Moderate	Premium format, packaging-sensitive
Taste-masked multiparticulate	High	Higher	Potential formulation moat
Extended-release tablet	High	Potentially higher	Limited need for routine allergy treatment
Combination product	High	Potentially higher	Regulatory and clinical complexity

A company can create patentable subject matter around a specific excipient ratio, taste-masking system, manufacturing process, particle architecture, or stability profile. Patentability does not guarantee commercial value. The claim must cover a product that is difficult to design around and has enough market demand to support development and enforcement costs.

What commercial opportunities exist for cetirizine 5 mg tablets?

The strongest opportunities are channel-specific rather than molecule-specific.

Store-brand and private-label supply

Retail chains, pharmacy groups, wholesalers, and e-commerce platforms need reliable low-cost cetirizine products. A manufacturer with efficient direct compression, validated suppliers, and flexible packaging can compete for private-label contracts.

The key commercial metrics are:

• Cost per tablet
• Minimum order quantity
• Supply continuity
• Shelf life
• Packaging flexibility
• Ability to support multiple national labels
• Recall and quality-system performance

Pediatric and family products

A 5 mg strength supports pediatric use and enables a product architecture built around chewables, flavored tablets, mini-tablets, or age-specific packaging. The opportunity is strongest where the product improves administration without requiring refrigerated storage or liquid measuring devices.

Allergen-conscious formulations

Lactose-free, gluten-free where supportable, dye-free, sugar-free, and vegetarian formulations can address consumer preferences. These claims require disciplined supplier qualification and label substantiation. They can support modest price premiums but do not create a strong barrier by themselves.

Institutional and travel packaging

Unit-dose blister packs, small-count bottles, and portable packs can target hospitals, clinics, travel retailers, convenience stores, and online subscription channels. Packaging convenience may produce more practical differentiation than another conventional excipient change.

How does cetirizine compare with competing antihistamines?

Cetirizine competes with loratadine, desloratadine, fexofenadine, levocetirizine, and diphenhydramine. Cetirizine’s 5 mg strength is useful for pediatric and dose-sensitive positioning, while its 10 mg strength is the principal adult benchmark.

Product	Typical differentiation	Excipient opportunity
Cetirizine	Broad allergy use; 5 mg and 10 mg strengths	Chewable, ODT, lactose-free
Loratadine	Low-sedation positioning	Chewable and rapidly dissolving products
Fexofenadine	Non-sedating positioning	High tablet-size and swallowability focus
Levocetirizine	Enantiomer-based branded positioning	Premium formulation and pediatric formats
Diphenhydramine	Older sedating antihistamine	Lower-cost tablets, liquids, and sleep products

Cetirizine’s main commercial weakness is intense generic competition. Its main formulation advantage is the ability to support multiple consumer-friendly dosage forms at a low active dose.

What generic launch scenarios exist?

A standard launch would likely follow one of three models:

1. A low-cost 5 mg film-coated tablet for pharmacy, institutional, and private-label supply.
2. A lactose-free or dye-free tablet for retail differentiation.
3. A chewable or ODT for pediatric and direct-to-consumer channels.

The first model has the lowest development risk but the weakest pricing power. The third model has better differentiation but requires more work on taste, disintegration, packaging, consumer acceptance, and regulatory documentation.

A dual launch using a conventional tablet and a differentiated chewable can improve manufacturing utilization while allowing separate price points. The conventional tablet establishes volume; the chewable captures higher-margin demand.

What is the revenue exposure and competitive outlook?

Cetirizine is a high-volume, low-margin generic category. Revenue exposure is driven by unit volume, retail distribution, private-label contracts, and the ability to avoid direct price comparison.

A conventional tablet manufacturer should expect:

• Low switching costs for buyers
• Significant tender and wholesaler pressure
• Limited brand loyalty
• Heavy competition from established generic manufacturers
• Greater pricing stability in differentiated pediatric forms
• Higher margin potential in contract-manufactured private-label products

No biosimilar risk exists because cetirizine is a small-molecule drug. The principal competitive risk is substitution by other antihistamines and by alternative cetirizine dosage forms.

What is the geographic opportunity for cetirizine tablets?

Cetirizine is marketed broadly across North America, Europe, Asia-Pacific, Latin America, and other regions. Regulatory classification differs by country. Some markets treat cetirizine as OTC, while others retain pharmacy or prescription controls for particular strengths or formulations.

A manufacturer seeking geographic expansion should separate:

• API and finished-product registration
• OTC versus prescription classification
• Labeling and pediatric dosing requirements
• Permitted excipients and colorants
• Serialization and packaging obligations
• Local bioequivalence expectations
• Import and batch-release requirements

The same core formulation can support multiple markets if the manufacturer keeps coating colors, sweeteners, allergens, tablet markings, and packaging components modular.

Key Takeaways

• Cetirizine hydrochloride 5 mg tablets have low active-ingredient patent risk and low conventional manufacturing complexity.
• Standard immediate-release tablets are commercially commoditized.
• The most practical excipient strategy uses a conventional filler-disintegrant-lubricant system with strong blend-uniformity controls.
• Lactose-free, dye-free, sugar-free, chewable, ODT, and pediatric mini-tablet formats offer the clearest differentiation.
• Taste masking is the central formulation issue for chewables and ODTs.
• No biosimilar risk exists, and Paragraph IV litigation is unlikely for ordinary tablets.
• Private-label, retail, pediatric, and travel-packaging channels offer the strongest commercial opportunities.
• A two-product strategy combining a low-cost standard tablet with a differentiated pediatric product can balance volume and margin.

FAQs

Can cetirizine 5 mg tablets be manufactured by direct compression?

Yes. Direct compression is suitable when the API and excipient grades provide adequate flow, content uniformity, compressibility, and dissolution. Low-dose blending and segregation control are the main technical risks.

Is lactose-free cetirizine commercially attractive?

Yes. Lactose-free positioning can support retail differentiation and broaden procurement eligibility. It is more commercially useful when combined with dye-free, sugar-free, or vegetarian positioning.

What excipient is best for cetirizine chewable tablets?

Mannitol is often useful because it supports compressibility, sweetness perception, and a cooling mouthfeel. The final system may also require a high-efficiency sweetener, flavor, taste-masking agent, and a chewable-grade lubricant.

Are cetirizine 5 mg tablets subject to biosimilar competition?

No. Cetirizine hydrochloride is a small-molecule active ingredient. Competition occurs through generic drugs, OTC products, branded generics, and alternative antihistamines.

Can a new cetirizine formulation receive patent protection?

Potentially, but protection would need to arise from a novel and non-obvious formulation, delivery system, manufacturing process, or stability solution. A routine excipient substitution is unlikely to create a commercially strong patent position.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs, NDA 019835, Zyrtec. https://www.accessdata.fda.gov/scripts/cder/daf/

2. U.S. Food and Drug Administration. (2022). Nasal decongestant, antiasthmatic, and antihistamine drug products for over-the-counter human use. 21 C.F.R. Part 341. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341

3. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/

4. National Library of Medicine. (n.d.). DailyMed: Cetirizine hydrochloride tablet labels. https://dailymed.nlm.nih.gov/dailymed/